查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2055600

癌症生技藥品市場：產業趨勢及全球預測（至2035年）－依生技藥品類型、標靶適應症及地區分類

Cancer Biologics Market: Industry Trends and Global Forecasts Till 2035 - Distribution by Type of Biologic, Target Indication and Geography
出版日期: | 出版商: Roots Analysis | 英文 77 Pages | 商品交期: 最快1-2個工作天內

價格

癌症生技藥品市場概覽

預計到 2035 年，全球癌症生技藥品市場規模將以 8.9% 的年複合成長率成長，從目前的 1,690 億美元成長到 1,890 億美元。

癌症生技藥品市場

市場規模和機會分析是根據以下參數進行細分的：

生技藥品類型

  • 抗體
  • 細胞和基因治療
  • 溶瘤病毒療法
  • 系統發育療法和疫苗
  • 核苷酸藥物
  • 胜肽
  • 其他

針對性適應症

  • 血癌
  • 肺癌
  • 結腸癌
  • 乳癌
  • 攝護腺癌
  • 皮膚癌
  • 腎癌
  • 子宮頸癌和胃癌
  • 肝癌
  • 膀胱癌
  • 卵巢癌
  • 胰臟癌
  • 頭頸癌
  • 腦癌
  • 其他類型的癌症

地區

  • 北美洲
  • 美國
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他歐洲國家
  • 亞太地區
  • 印度
  • 日本
  • 韓國
  • 中國
  • 其他地區

癌症生技藥品市場：成長與趨勢

根據世界癌症大會的數據，癌症是全球第三大死因，僅次於心血管疾病和感染疾病。目前有多種治療方法可供選擇，包括手術、放射治療方法和化學療法。其中，手術仍然是主要的治療方法，尤其適用於早期診斷的癌症。放射線治療通常與手術合併使用，由醫護人員進行局部治療。多年來，在各種癌症的藥物治療方法（包括生物製藥和小分子化合物）方面取得了顯著進展。

生物製藥，例如單株抗體、雙特異性抗體以及細胞和基因療法，旨在靶向並調節特定的生物路徑。值得注意的是，生物製藥約佔癌症治療市場的70%。例如，默克公司開發的KEYTRUDA®和強生公司開發的Darzalex®都已核准用於治療癌症，據報道，它們的最新銷售額分別為300億美元和120億美元。這表明這些癌症療法具有重要的臨床和商業性價值。同時，小分子藥物在癌症治療中繼續發揮至關重要的作用，這主要歸功於它們能夠穿透細胞並影響細胞內訊號通路。

近年來，癌症生技藥品市場在精準標靶和個人化治療癌細胞的技術方面取得了顯著進展，包括次世代定序、CRISPR-Cas9基因標靶化、單細胞分析、雙特異性抗體、抗體藥物複合體（ADC）、CAR-T細胞療法和mRNA療法/疫苗。這些進步，加上癌症發病率的上升以及對高效、標靶和個人化療法日益成長的需求，正在推動癌症生技藥品市場的成長。

成長要素－市場擴張的策略促進因素

多種因素正在推動癌症生物製劑市場的成長，包括全球癌症發病率上升、細胞和基因療法研發管線不斷擴展、對個人化醫療的日益重視，以及製藥公司在免疫療法和聯合治療投入的增加。此外，對個人化癌症生物製劑市場的日益關注促使許多製藥公司進入該市場，致力於開發創新治療方法。這些治療方法旨在為各種類型的癌症拓展替代治療方案，同時確保療效的持續性。為了因應癌症治療領域的快速發展，製藥公司正投資於改造免疫細胞、溶瘤病毒和基因工程技術，以提供高度標靶且療效持久的治療方案，滿足每位患者的獨特需求。這些進展表明，生物技術正在對癌症生物製劑市場產生重大影響。

市場挑戰－阻礙進展的主要障礙

癌症生技藥品產業面臨高昂的研發和生產成本，阻礙了中小企業進入該領域，也抑制了創新。諸如細胞株最佳化等複雜流程往往導致每種藥物的成本超過數十億美元。監管壁壘，特別是對於抗體藥物複合體（ADC）等強效治療方法而言，需要進行嚴格的臨床試驗和安全性評估，這使得上市時間延遲數年。供應鏈脆弱性，例如樹脂和管瓶短缺以及低溫運輸物流方面的挑戰，因地緣政治緊張局勢而進一步加劇，導致生產延誤。此外，專利到期加劇了競爭，生物相似藥壓低價格，搶佔原廠藥的市場佔有率。對免疫抗原性、輸注反應和嚴重副作用的擔憂削弱了患者的信心和接受度。此外，高昂的治療費用（通常每年高達數萬美元）限制了發展中國家的准入。這些壓力，加上小分子藥物和化療的競爭，阻礙了儘管需求不斷成長，但該行業的持續成長卻舉步維艱。

癌症生技藥品市場—關鍵洞察

本報告詳細分析了癌症生技藥品市場的現狀，並指出了該行業潛在的成長機會。報告的主要發現包括：

  • 隨著新藥的問世，必須從「統一」的給藥方式轉向個體化的給藥策略，以避免給藥不足或過量。目前，業界已核准多種類型的抗體藥物複合體（ADC）。例如，PADVEC® 被批准用於轉移性尿路上皮癌的二線治療，BESPONSA® 被批准用於 CD22 陽性急性淋巴性白血病的治療，ZYNLONTA® 被批准用於瀰漫性大 B 細胞淋巴瘤的三線治療。
  • 對於罕見淋巴瘤患者，現有的根治性治療方法尚未能達到完全緩解。在某些情況下，復發或難治性患者的中位存活期僅為 6 至 10 個月。因此，患者報告結局 (PRO) 在目前的臨床試驗中變得越來越重要，能夠更準確地反映真實世界的臨床經驗。將患者自述資訊納入試驗設計有助於臨床醫師為這類罕見疾病患者族群制定個人化的最佳化治療策略。
  • 尿路上皮癌（又稱移行細胞癌）佔全球膀胱癌病例的 80-90%，並根據是否有肌肉浸潤進一步分類。
  • 儘管膀胱癌領域有多種治療方法，但仍需要耐受性更好、能改善無惡化生存期(PFS) 的藥物。
  • 評估癌症生技藥品市場的關鍵促進因素和障礙，可以為相關人員提供寶貴的見解，並使他們能夠改善產品和服務，以適應不斷變化的需求。
癌症生物製劑市場-IMG1
  • 目前，癌症生技藥品市場集中在北美，但預計未來幾年亞太市場將呈現更高的成長率。
  • 預計今年北美癌症生技藥品市場將佔最大佔有率。此外，就標靶適應症而言，乳癌預計在預測期內將以較高的年複合成長率成長。
癌症生物製劑市場 - IMG2
  • 受腫瘤疾病日益普遍以及對標靶治療開發的重視所推動，預計美國癌症生技藥品市場在預測期內將以 9.1% 的年複合成長率成長。

癌症生技藥品市場：主要細分市場

mRNA療法和疫苗將是癌症治療的未來。

就生物製劑類型而言，市場區隔包括抗體、細胞和基因療法、溶瘤病毒療法、mRNA療法和疫苗、核苷酸類藥物、胜肽類藥物以及其他生物製劑。預計到2035年，抗體市場將佔整個市場的70%。這一成長主要歸功於抗體的高特異性，以及它們能夠精準靶向癌細胞並最大限度減少對健康細胞的損傷。值得注意的是，mRNA療法和疫苗市場預計將呈現更高的年複合成長率。特別是，製藥公司預計，在臨床試驗中展現出良好前景的mRNA療法和疫苗（例如BNT113、mRNA-4157和GRT-C901/GRT-R902）將在不久的將來成為重磅產品，從而推動行業的顯著擴張。

血液疾病正在推動生技藥品市場的發展。

依標靶適應症分類，市場可分為血液腫瘤、肺癌、大腸直腸癌、乳癌、皮膚癌、腎癌、子宮頸癌和胃癌、肝癌、卵巢癌、胰臟癌、頭頸癌、腦腫瘤和其他癌症。根據癌症生物製劑市場預測，血液腫瘤類別約佔總收入的20%。這一最大的市場佔有率被認為是由於各種血液腫瘤標靶治療提高了患者的存活率。預計未來幾年，乳癌領域將在整個預測期內保持最高的年複合成長率。尤其值得一提的是，乳癌占美國女性癌症病例的30%，製藥公司正在大力推動乳癌的臨床研究和藥物開發，以最大限度地減少副作用。

北美地區創造了可觀的收入。

從區域來看，市場細分將整體市場分類為北美、歐洲和亞太地區。我們對全球癌症生技藥品市場的分析表明，北美市場佔據主導地位，佔總銷售額的45%。這一主導地位歸功於北美較高的癌症發病率、持續的技術進步以及有利於癌症生技藥品研發的法規結構。值得注意的是，美國在北美癌症生技藥品領域處於領先地位，這得益於其先進的醫療保健體系、對慢性疾病的廣泛研究以及對個人化癌症治療日益成長的需求。

第一次調查總結

本市場報告中提出的觀點和見解也受到與主要產業相關人員討論的影響。本市場報告還包含與以下第三方進行的討論記錄：

  • 美國某公立研究型大學的校長
  • 美國某醫院臨床護理主任
  • 美國一家大型企業的副總裁
  • 瑞典一所公立研究型大學的教授
  • 英國一所公立研究型大學的教授

生技藥品市場主要公司範例

  • Abbott
  • AbbVie
  • Amgen
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda Pharmaceuticals

癌症生技藥品市場：研究範圍

  • 市場規模和機會分析：本報告對癌症生技藥品市場進行了詳細分析，重點關注關鍵市場細分，例如 [A]生技藥品類型、[B] 目標適應症和 [C] 地區。
  • 公司簡介：我們提供北美、歐洲和亞太地區從事癌症生技藥品開發的領先公司的詳細簡介，依據是[A]成立年份，[B]總部所在地，[C]癌症生技藥品產品組合，[D]近期發展，以及[E]基於資訊的未來展望。
  • 未滿足的需求和治療指南：本模組介紹了涵蓋多種適應症的治療指南，全面概述了目前的治療方法。這些指引整合了實證治療建議，確保臨床安全，並評估特定適應症中未滿足的需求。
  • 市場影響分析：這是對可能影響癌症生技藥品產業成長的因素進行詳細的分析。它還包括對[A]關鍵促進因素、[B]潛在阻礙因素、[C]新興機會和[D]現有挑戰的識別和分析。

目錄

第1章 背景

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章執行摘要

第6章：引言

  • 癌症概述
  • 癌症治療的支柱
  • 癌症治療類型
  • 癌症生技藥品的主要優勢
  • 未來展望

第7章：公司簡介

  • 章節概要
  • Abbott
  • AbbVie
  • Amgen
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson &Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda Pharmaceuticals

第8章：未滿足的需求和治療指南

  • 膀胱癌
    • 治療指南
    • 膀胱癌治療中未滿足的需求
  • 血癌
  • 腦腫瘤
  • 乳癌
  • 結腸癌
  • 頭頸癌
  • 肝癌
  • 肺癌
  • 攝護腺癌

第9章 市場影響分析

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場挑戰

第10章：全球癌症治療生技藥品市場

  • 主要先決條件
  • 預測性調查方法
  • 全球癌症治療生技藥品市場（至2035年）
  • 主要市場區隔

第11章：癌症治療生技藥品市場（以生技藥品類型分類）

第12章：癌症生技藥品市場（依標靶適應症分類）

第13章：生技藥品市場（按地區分類）

第14章 市場預測機會分析：北美

第15章 市場預測機會分析：歐洲

第16章 市場預測機會分析：亞太地區

第17章 市場預測機會分析：其他地區

第18章 結論

第19章附錄一：表格形式數據

第20章 附錄二：公司列表

Product Code: RA100377

Cancer Biologics Market: Overview

As per Roots Analysis, the global cancer biologics market is estimated to grow from USD 169 billion in the current year to USD 189 billion by 2035, at a CAGR of 8.9% during the forecast period, till 2035.

Cancer Biologics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologic

  • Antibodies
  • Cell and Gene Therapies
  • Oncolytic Viral Therapies
  • mRNA Therapies and Vaccines
  • Nucleotide-based Drugs
  • Peptides
  • Other Biologics

Target Indication

  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Skin Cancer
  • Renal Cancer
  • Cervical and Gastric Cancer
  • Liver Cancer
  • Bladder Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Head and Neck Cancer
  • Brain Cancer
  • Other Type of Cancer

Geography

  • North America
  • US
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • India
  • Japan
  • South Korea
  • China
  • Rest of the World

Cancer Biologics Market: Growth and Trends

According to the World Cancer Congress, cancer ranks as the third most common cause of death worldwide, following cardiovascular diseases and infections. Presently, there are numerous treatment options available, including surgical procedures, radiotherapy, and drug therapies. Among these approaches, surgery is the primary method of treatment, especially for cancers diagnosed at an early stage. Radiotherapy is often used in conjunction with surgery and is administered in a localized manner by medical professionals. Over the years, the development of drug-based treatments (including both biologics and small molecules) has seen significant growth for various cancer types.

Biologic therapies, such as monoclonal antibodies, bispecific antibodies, and cell and gene therapies, aim to target and modify specific biological pathways. It is worth noting that biologics represent nearly 70% of the market for cancer therapeutics. For instance, KEYTRUDA(R) (developed by Merck) and Darzalex(R) (developed by Johnson & Johnson) have received approvals for treating oncological disorders, with reported sales of USD 30 billion and USD 12 billion, respectively, in recent years. This highlights the considerable clinical and commercial significance of these cancer treatments. Simultaneously, small molecule drugs continue to be fundamental in cancer treatment, primarily due to their capability to penetrate cells and influence intracellular signaling pathways.

The cancer biologics market has seen significant advancements in recent years, including next-generation sequencing, CRISPR-Cas9 gene editing, single-cell analysis, bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T cell therapies, and mRNA therapies / vaccines, which enable precise targeting of cancer cells and personalized treatments. Owing to these advancements and the rising incidence of cancer, coupled with the heightened demand for targeted and highly effective personalized treatments, is propelling the growth of the cancer biologics market.

Growth Drivers: Strategic Enablers of Market Expansion

Various drivers are propelling the growth of cancer biologics market including the rising global incidence of cancer, expanding pipelines for cell and gene therapies, growing focus on personalized medicine, and increased R&D investments by pharmaceutical companies in immunotherapy and combination therapies. Further, the heightened attention on the personalized cancer biologics therapy market has attracted numerous pharmaceutical firms to develop innovative treatments, designed to ensure lasting responses while broadening alternative treatments for various cancer types. These rapid advancements in cancer therapies has prompted pharmaceutical firms to invest in modified immune cells, oncolytic viruses, and gene-altered technologies, providing highly targeted, durable treatment options customized to each patient's unique profile. These advancements have demonstrated a considerable influence of biotechnology on the cancer biologics market.

Market Challenges: Critical Barriers Impeding Progress

The cancer biologics sector faces high development and production expenses that discourage smaller companies and hinder innovation, frequently surpassing billions per drug due to complex procedures such as cell line optimization. Regulatory obstacles necessitate stringent clinical trials and safety evaluations, especially for powerful treatments such as ADCs, postponing market introduction by several years. Supply chain weaknesses, such as shortages of resins, vials, and cold chain logistics, worsen production delays in the context of geopolitical tensions. Further, patent expirations allow biosimilars to reduce prices and gain market share from original products, increasing competition. Concerns like immunogenicity, infusion reactions, and serious side effects erode patient confidence and acceptance. Furthermore, expensive therapy expenses, often amounting to tens of thousands each year also restrict access in developing markets. These pressures, along with competition from small molecules and chemotherapy, hinder consistent growth even with increasing demand

Cancer Biologics Market: Key Insights

The report delves into the current state of the cancer biologics market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • With the introduction of new medications, it's essential to transition from a "one-size-fits-all" method to tailored dosing strategies to prevent under- or overdosing. The industry has seen the endorsement of antibody drug conjugates for different types; for example, PADVEC(R) for second-line treatment of metastatic urothelial carcinoma, BESPONSA(R) for CD22-positive acute lymphoblastic leukemia, and ZYNLONTA(R) for third-line therapy of diffuse large B-cell lymphoma.
  • In individuals with uncommon lymphomas, existing treatments fail to achieve a complete cure, even though they are intended to be curative. In certain instances, the median survival for relapsed / refractory patients ranges from six to ten months. Consequently, current clinical trials are increasingly emphasizing patient-reported outcomes to more accurately reflect real-world experiences. Integrating self-reported information into trial design can assist clinicians in customizing treatment strategies for this uncommon group of patients.
  • Urothelial cancer (also known as transitional cell carcinoma) accounts for 80-90% of the bladder cancer cases worldwide and is further segregated based on muscle invasiveness.
  • Despite the wide availability of various types of therapies, the bladder cancer segment requires drugs that offer better tolerability and improve progression-free survival (PFS)
  • Assessment of the key drivers and barriers in the cancer biologics market provides valuable insights to stakeholders, allowing them to enhance their offerings to adapt to the evolving needs.
Cancer Biologics Market - IMG1
  • Presently, the cancer biologics market is more concentrated in North America; however, the market in Asia-Pacific is likely to witness higher growth rate in the coming years.
  • The cancer biologics market in North America is expected to capture maximum share in the current year; further, in terms of target indication, breast cancer is likely to grow at a higher CAGR during the forecast period.
Cancer Biologics Market - IMG2
  • Driven by the rising prevalence of oncological disorders and focus on targeted therapy development, the cancer biologics market in the US is expected to grow at CAGR of 9.1%, during the forecast period.

Cancer Biologics Market: Key Segments

mRNA Therapies and Vaccines to be the Future of Cancer Treatment

In terms of type of biologic, the market is segmented across antibodies, cell and gene therapies, oncolytic viral therapies, mRNA therapies and vaccines, nucleotide-based drugs, peptides and other biologics. In 2035, the antibodies segment is likely to account for 70% of the total market share. This increase arises from the ability of antibodies to possess high specificity, allowing them to accurately target cancer cells while reducing harm to healthy cells. It is crucial to emphasize that the segment for mRNA therapies and vaccines is expected to experience a greater CAGR. Significantly, the pharmaceutical companies anticipate that the mRNA treatments and vaccines (such as BNT113, mRNA-4157, and GRT-C901 / GRT-R902), which have demonstrated encouraging outcomes in clinical trials, will attain blockbuster status in the near future, signaling substantial industry expansion.

Blood Disorders Dominate the Cancer Biologics Industry

In terms of the target indication, the overall market is segmented across blood cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, skin cancer, renal cancer, Cervical and Gastric Cancer, liver cancer, bladder cancer, ovarian cancer, pancreatic cancer, head and neck cancer, brain cancer, other types of cancer. As per the forecast for the cancer biologics market, the blood cancer category contributes nearly 20% of total revenue. This largest market share is likely to be a result of improved survival rates attained through different targeted treatments for blood cancer. In the coming years, the breast cancer sector is expected to expand at the highest CAGR throughout the forecast duration. Significantly, breast cancer represents 30% of all cancer cases among women in the US, prompting pharmaceutical firms to push forward with breast oncology studies and drug development that minimize side effects.

North America Generates High Revenue

In terms of geography, the overall market is segmented across North America, Europe and Asia-Pacific. Our analysis of the global cancer biologics market shows that North America leads the market by capturing 45% of the total revenue share. This prevalence is probably due to elevated cancer rates, continuous technological progress, and advantageous regulatory frameworks that aid the advancement of cancer biologics. It is worth highlighting that within North America, The US leads the cancer biologics sector, propelled by advanced healthcare systems, robust research in chronic illnesses, and increasing demand for tailored cancer treatment.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes transcripts of the following other third-party discussions:

  • Director, Public Research University in the US
  • Clinical Director, Hospital in the US
  • Vice-President, Large Company in the US
  • Professor, Public Research University in Sweden
  • Professor, Public Research University in the UK

Example Players in Cancer Biologics Market

  • Abbott
  • AbbVie
  • Amgen
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda Pharmaceuticals

Cancer Biologics Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cancer biologics market, focusing on key market segments, including [A] type of biologic, [B] target indication, and [C] geography.
  • Company Profiles: In-depth profiles of prominent players North America, Europe and Asia-Pacific that are engaged in the development of cancer biologics based on [A] year of establishment, [B] location of headquarters, [C] cancer biologics portfolio, [D] recent developments and [E] an informed future outlook.
  • Unmet Needs and Treatment Guidelines: The module presents treatment guidelines across a range of indications, providing a comprehensive overview of current treatment regimen. The guidelines synthesize evidence-based recommendations for therapy, ensuring safe clinical care and assessing the unmet needs in the treatment of a particular indication.
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of cancer biologics industry. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D]existing challenges.

Key Questions Answered in this Report

  • Which region dominates the cancer biologics market?
  • What are the key trends observed in the cancer biologics market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by cancer biologic developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Value and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product (GDP)
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross-Border Dynamics
  • 4.3. Concluding Remarks

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Overview of Cancer
  • 6.2. Pillars of Cancer Therapy
  • 6.3. Types of Cancer Treatments
  • 6.4. Key Benefits of Cancer Biologics
  • 6.5. Future Perspective

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Abbott
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Cancer Biologics Portfolio
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. AbbVie
  • 7.4. Amgen
  • 7.5. AstraZeneca
  • 7.6. BioNTech
  • 7.7. Bristol Myers Squibb
  • 7.8. Eli Lilly and Company
  • 7.9. Gilead Sciences
  • 7.10. GlaxoSmithKline
  • 7.11. Johnson & Johnson
  • 7.12. Merck
  • 7.13. Novartis
  • 7.14. Pfizer
  • 7.15. Roche
  • 7.16. Sanofi
  • 7.17. Takeda Pharmaceuticals

8. UNMET NEEDS AND TREATMENT GUIDELINES

  • 8.1. Bladder Cancer
    • 8.1.1. Treatment Guidelines
    • 8.1.2. Unmet Need in Bladder Cancer Treatment
  • 8.2. Blood Cancer
  • 8.3. Brain Cancer
  • 8.4. Breast Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Head and Neck Cancer
  • 8.7. Liver Cancer
  • 8.8. Lung Cancer
  • 8.9. Prostate Cancer

9. MARKET IMPACT ANALYSIS

  • 9.1. Market Drivers
  • 9.2. Market Restraints
  • 9.3. Market Opportunities
  • 9.4. Market Challenges

10. GLOBAL CANCER BIOLOGICS MARKET

  • 10.1. Key Assumptions
  • 10.2. Forecast Methodology
  • 10.3. Global Cancer Biologics Market, Till 2035
    • 10.3.1. Multivariate Scenario Analysis
      • 10.3.1.1. Conservative Scenario
      • 10.3.1.2. Optimistic Scenario
  • 10.5. Key Market Segmentations

11. CANCER BIOLOGICS MARKET, BY TYPE OF BIOLOGIC

  • 11.1. Cancer Biologics Market: Distribution by Type of Biologic
    • 11.1.1. Cancer Biologics Market for Antibodies, Forecasted Estimates (Till 2035)
    • 11.1.2. Cancer Biologics Market for Cell and Gene Therapies, Forecasted Estimates (Till 2035)
    • 11.1.3. Cancer Biologics Market for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
    • 11.1.4. Cancer Biologics Market for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
    • 11.1.5. Cancer Biologics Market for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
    • 11.1.6. Cancer Biologics Market for Peptides, Forecasted Estimates (Till 2035)
  • 11.2. Data Triangulation and Validation

12. CANCER BIOLOGICS MARKET, BY TARGET INDICATION

  • 12.1. Cancer Biologics Market: Distribution by Target Indication
    • 12.1.1. Cancer Biologics Market for Blood Cancer, Forecasted Estimates (Till 2035)
    • 12.1.2. Cancer Biologics Market for Lung Cancer, Forecasted Estimates (Till 2035)
    • 12.1.3. Cancer Biologics Market for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 12.1.4. Cancer Biologics Market for Breast Cancer, Forecasted Estimates (Till 2035)
    • 12.1.5. Cancer Biologics Market for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 12.1.6. Cancer Biologics Market for Skin Cancer, Forecasted Estimates (Till 2035)
    • 12.1.7. Cancer Biologics Market for Renal Cancer, Forecasted Estimates (Till 2035)
    • 12.1.8. Cancer Biologics Market for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
    • 12.1.9. Cancer Biologics Market for Liver Cancer, Forecasted Estimates (Till 2035)
    • 12.1.10. Cancer Biologics Market for Bladder Cancer, Forecasted Estimates (Till 2035)
    • 12.1.11. Cancer Biologics Market for Ovarian Cancer, Forecasted Estimates (Till 2035)
    • 12.1.12. Cancer Biologics Market for Pancreatic Cancer, Forecasted Estimates (Till 2035)
    • 12.1.13. Cancer Biologics Market for Head and Neck Cancer, Forecasted Estimates (Till 2035)
    • 12.1.14. Cancer Biologics Market for Brain Cancer, Forecasted Estimates (Till 2035)
    • 12.1.15. Cancer Biologics Market for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • 12.2. Data Triangulation and Validation

13. CANCER BIOLOGICS MARKET, BY GEOGRAPHY

  • 13.1. Cancer Biologics Market: Distribution by Geography
    • 13.1.1. Cancer Biologics Market in North America, Forecasted Estimates (Till 2035)
    • 13.1.2. Cancer Biologics Market in the US, Forecasted Estimates (Till 2035)
    • 13.1.2. Cancer Biologics Market in Europe, Forecasted Estimates (Till 2035)
      • 13.1.2.1. Cancer Biologics Market in Germany, Forecasted Estimates (Till 2035)
      • 13.1.2.2. Cancer Biologics Market in France, Forecasted Estimates (Till 2035)
      • 13.1.2.3. Cancer Biologics Market in the UK, Forecasted Estimates (Till 2035)
      • 13.1.2.4. Cancer Biologics Market in Spain, Forecasted Estimates (Till 2035)
      • 13.1.2.5. Cancer Biologics Market in Rest of Europe, Forecasted Estimates (Till 2035)
    • 13.1.3. Cancer Biologics Market in Asia-Pacific, Forecasted Estimates (Till 2035)
      • 13.1.3.1. Cancer Biologics Market in India, Forecasted Estimates (Till 2035)
      • 13.1.3.2. Cancer Biologics Market in Japan, Forecasted Estimates (Till 2035)
      • 13.1.3.3. Cancer Biologics Market in South Korea, Forecasted Estimates (Till 2035)
      • 13.1.3.4. Cancer Biologics Market in China, Forecasted Estimates (Till 2035)
    • 13.1.4. Cancer Biologics Market in Rest of the World, Forecasted Estimates (Till 2035)
  • 13.2. Data Triangulation and Validation

14. MARKET FORECAST OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 14.1. Cancer Biologics Market in North America: Distribution by Type of Biologic
    • 14.1.1. Cancer Biologics Market in North America for Antibodies, Forecasted Estimates (Till 2035)
    • 14.1.2. Cancer Biologics Market in North America for Cell and Gene Therapies Forecasted Estimates (Till 2035)
    • 14.1.3. Cancer Biologics Market in North America for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
    • 14.1.4. Cancer Biologics Market in North America for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
    • 14.1.5. Cancer Biologics Market in North America for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
    • 14.1.6. Cancer Biologics Market in North America for Peptides, Forecasted Estimates (Till 2035)
  • 14.2. Cancer Biologics Market in North America: Distribution by Target Indication
    • 14.2.1. Cancer Biologics Market in North America for Blood Cancer, Forecasted Estimates (Till 2035)
    • 14.2.2. Cancer Biologics Market in North America for Lung Cancer, Forecasted Estimates (Till 2035)
    • 14.2.3. Cancer Biologics Market in North America for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 14.2.4. Cancer Biologics Market in North America for Breast Cancer, Forecasted Estimates (Till 2035)
    • 14.2.5. Cancer Biologics Market in North America for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 14.2.6. Cancer Biologics Market in North America for Skin Cancer, Forecasted Estimates (Till 2035)
    • 14.2.7. Cancer Biologics Market in North America for Renal Cancer, Forecasted Estimates (Till 2035)
    • 14.2.8. Cancer Biologics Market in North America for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
    • 14.2.9. Cancer Biologics Market in North America for Liver Cancer, Forecasted Estimates (Till 2035)
    • 14.2.10. Cancer Biologics Market in North America for Bladder Cancer, Forecasted Estimates (Till 2035)
    • 14.2.11. Cancer Biologics Market in North America for Ovarian Cancer, Forecasted Estimates (Till 2035)
    • 14.2.12. Cancer Biologics Market in North America for Pancreatic Cancer, Forecasted Estimates (Till 2035)
    • 14.2.13. Cancer Biologics Market in North America for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 14.2.14. Cancer Biologics Market in North America for Brain Cancer, Forecasted Estimates (Till 2035)
    • 14.2.15. Cancer Biologics Market in North America for Other Type of Cancer, Forecasted Estimates (Till 2035)

15. MARKET FORECAST OPPORTUNITY ANALYSIS: EUROPE

  • 15.1. Cancer Biologics Market in Europe: Distribution by Type of Biologic
    • 15.1.1. Cancer Biologics Market in Europe for Antibodies, Forecasted Estimates (Till 2035)
    • 15.1.2. Cancer Biologics Market in Europe for Cell and Gene Therapies Forecasted Estimates (Till 2035)
    • 15.1.3. Cancer Biologics Market in Europe for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
    • 15.1.4. Cancer Biologics Market in Europe for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
    • 15.1.5. Cancer Biologics Market in Europe for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
    • 15.1.6. Cancer Biologics Market in Europe for Peptides, Forecasted Estimates (Till 2035)
  • 15.2. Cancer Biologics Market in Europe: Distribution by Target Indication
    • 15.2.1. Cancer Biologics Market in Europe for Blood Cancer, Forecasted Estimates (Till 2035)
    • 15.2.2. Cancer Biologics Market in Europe for Lung Cancer, Forecasted Estimates (Till 2035)
    • 15.2.3. Cancer Biologics Market in Europe for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 15.2.4. Cancer Biologics Market in Europe for Breast Cancer, Forecasted Estimates (Till 2035)
    • 15.2.5. Cancer Biologics Market in Europe for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 15.2.6. Cancer Biologics Market in Europe for Skin Cancer, Forecasted Estimates (Till 2035)
    • 15.2.7. Cancer Biologics Market in Europe for Renal Cancer, Forecasted Estimates (Till 2035)
    • 15.2.8. Cancer Biologics Market in Europe for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
    • 15.2.9. Cancer Biologics Market in Europe for Liver Cancer, Forecasted Estimates (Till 2035)
    • 15.2.10. Cancer Biologics Market in Europe for Bladder Cancer, Forecasted Estimates (Till 2035)
    • 15.2.11. Cancer Biologics Market in Europe for Ovarian Cancer, Forecasted Estimates (Till 2035)
    • 15.2.12. Cancer Biologics Market in Europe for Pancreatic Cancer, Forecasted Estimates (Till 2035)
    • 15.2.13. Cancer Biologics Market in Europe for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 15.2.14. Cancer Biologics Market in Europe for Brain Cancer, Forecasted Estimates (Till 2035)
    • 15.2.15. Cancer Biologics Market in Europe for Other Type of Cancer, Forecasted Estimates (Till 2035)

16. MARKET FORECAST OPPORTUNITY ANALYSIS: ASIA-PACIFIC

  • 16.1. Cancer Biologics Market in Asia-Pacific: Distribution by Type of Biologic
    • 16.1.1. Cancer Biologics Market in Asia-Pacific for Antibodies, Forecasted Estimates (Till 2035)
    • 16.1.2. Cancer Biologics Market in Asia-Pacific for Cell and Gene Therapies, Forecasted Estimates (Till 2035)
    • 16.1.3. Cancer Biologics Market in Asia-Pacific for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
    • 16.1.4. Cancer Biologics Market in Asia-Pacific for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
    • 16.1.5. Cancer Biologics Market in Asia-Pacific for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
    • 16.1.6. Cancer Biologics Market in Asia-Pacific for Peptides, Forecasted Estimates (Till 2035)
  • 16.2. Cancer Biologics Market in Asia-Pacific: Distribution by Target Indication
    • 16.2.1. Cancer Biologics Market in Asia-Pacific for Blood Cancer, Forecasted Estimates (Till 2035)
    • 16.2.2. Cancer Biologics Market in Asia-Pacific for Lung Cancer, Forecasted Estimates (Till 2035)
    • 16.2.3. Cancer Biologics Market in Asia-Pacific for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 16.2.4. Cancer Biologics Market in Asia-Pacific for Breast Cancer, Forecasted Estimates (Till 2035)
    • 16.2.5. Cancer Biologics Market in Asia-Pacific for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 16.2.6. Cancer Biologics Market in Asia-Pacific for Skin Cancer, Forecasted Estimates (Till 2035)
    • 16.2.7. Cancer Biologics Market in Asia-Pacific for Renal Cancer, Forecasted Estimates (Till 2035)
    • 16.2.8. Cancer Biologics Market in Asia-Pacific for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
    • 16.2.9. Cancer Biologics Market in Asia-Pacific for Liver Cancer, Forecasted Estimates (Till 2035)
    • 16.2.10. Cancer Biologics Market in Asia-Pacific for Bladder Cancer, Forecasted Estimates (Till 2035)
    • 16.2.11. Cancer Biologics Market in Asia-Pacific for Ovarian Cancer, Forecasted Estimates (Till 2035)
    • 16.2.12. Cancer Biologics Market in Asia-Pacific for Pancreatic Cancer, Forecasted Estimates (Till 2035)
    • 16.2.13. Cancer Biologics Market in Asia-Pacific for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 16.2.14. Cancer Biologics Market in Asia-Pacific for Brain Cancer, Forecasted Estimates (Till 2035)
    • 16.2.15. Cancer Biologics Market in Asia-Pacific for Other Type of Cancer, Forecasted Estimates (Till 2035)

17. MARKET FORECAST OPPORTUNITY ANALYSIS: REST OF THE WORLD

  • 17.1. Cancer Biologics Market in Rest of the World: Distribution by Type of Biologic
    • 17.1.1. Cancer Biologics Market in Rest of the World for Antibodies, Forecasted Estimates (Till 2035)
    • 17.1.2. Cancer Biologics Market in Rest of the World for Cell and Gene Therapies Forecasted Estimates (Till 2035)
    • 17.1.3. Cancer Biologics Market in Rest of the World for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
    • 17.1.4. Cancer Biologics Market in Rest of the World for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
    • 17.1.5. Cancer Biologics Market in Rest of the World for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
    • 17.1.6. Cancer Biologics Market in Rest of the World for Peptides, Forecasted Estimates (Till 2035)
  • 17.2. Cancer Biologics Market in Rest of the World: Distribution by Target Indication
    • 17.2.1. Cancer Biologics Market in Rest of the World for Blood Cancer, Forecasted Estimates (Till 2035)
    • 17.2.2. Cancer Biologics Market in Rest of the World for Lung Cancer, Forecasted Estimates (Till 2035)
    • 17.2.3. Cancer Biologics Market in Rest of the World for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 17.2.4. Cancer Biologics Market in Rest of the World for Breast Cancer, Forecasted Estimates (Till 2035)
    • 17.2.5. Cancer Biologics Market in Rest of the World for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 17.2.6. Cancer Biologics Market in Rest of the World for Skin Cancer, Forecasted Estimates (Till 2035)
    • 17.2.7. Cancer Biologics Market in Rest of the World for Renal Cancer, Forecasted Estimates (Till 2035)
    • 17.2.8. Cancer Biologics Market in Rest of the World for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
    • 17.2.9. Cancer Biologics Market in Rest of the World for Liver Cancer, Forecasted Estimates (Till 2035)
    • 17.2.10. Cancer Biologics Market in Rest of the World for Bladder Cancer, Forecasted Estimates (Till 2035)
    • 17.2.11. Cancer Biologics Market in Rest of the World for Ovarian Cancer, Forecasted Estimates (Till 2035)
    • 17.2.12. Cancer Biologics Market in Rest of the World for Pancreatic Cancer, Forecasted Estimates (Till 2035)
    • 17.2.13. Cancer Biologics Market in Rest of the World for Colorectal Cancer, Forecasted Estimates (Till 2035)
    • 17.2.14. Cancer Biologics Market in Rest of the World for Brain Cancer, Forecasted Estimates (Till 2035)
    • 17.2.15. Cancer Biologics Market in Rest of the World for Other Type of Cancer, Forecasted Estimates (Till 2035)

18. CONCLUDING REMARKS

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES

List of Tables

  • Table 14.1 Cancer Biologics Market in North America: Distribution by Type of Biologic
  • Table 14.2 Cancer Biologics Market in North America for Antibodies, Forecasted Estimates (Till 2035)
  • Table 14.3 Cancer Biologics Market in North America for Cell and Gene Therapies Forecasted Estimates (Till 2035)
  • Table 14.4 Cancer Biologics Market in North America for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Table 14.5 Cancer Biologics Market in North America for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Table 14.6 Cancer Biologics Market in North America for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Table 14.7 Cancer Biologics Market in North America for Peptides, Forecasted Estimates (Till 2035)
  • Table 14.8 Cancer Biologics Market in North America: Distribution by Target Indication
  • Table 14.9 Cancer Biologics Market in North America for Blood Cancer, Forecasted Estimates (Till 2035)
  • Table 14.10 Cancer Biologics Market in North America for Lung Cancer, Forecasted Estimates (Till 2035)
  • Table 14.11 Cancer Biologics Market in North America for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 14.12 Cancer Biologics Market in North America for Breast Cancer, Forecasted Estimates (Till 2035)
  • Table 14.13 Cancer Biologics Market in North America for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Table 14.14 Cancer Biologics Market in North America for Skin Cancer, Forecasted Estimates (Till 2035)
  • Table 14.15 Cancer Biologics Market in North America for Renal Cancer, Forecasted Estimates (Till 2035)
  • Table 14.16 Cancer Biologics Market in North America for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Table 14.17 Cancer Biologics Market in North America for Liver Cancer, Forecasted Estimates (Till 2035)
  • Table 14.18 Cancer Biologics Market in North America for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Table 14.19 Cancer Biologics Market in North America for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Table 14.20 Cancer Biologics Market in North America for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Table 14.21 Cancer Biologics Market in North America for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 14.22 Cancer Biologics Market in North America for Brain Cancer, Forecasted Estimates (Till 2035)
  • Table 14.23 Cancer Biologics Market in North America for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Table 15.1 Cancer Biologics Market in Europe: Distribution by Type of Biologic
  • Table 15.2 Cancer Biologics Market in Europe for Antibodies, Forecasted Estimates (Till 2035)
  • Table 15.3 Cancer Biologics Market in Europe for Cell and Gene Therapies Forecasted Estimates (Till 2035)
  • Table 15.4 Cancer Biologics Market in Europe for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Table 15.5 Cancer Biologics Market in Europe for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Table 15.6 Cancer Biologics Market in Europe for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Table 15.7 Cancer Biologics Market in Europe for Peptides, Forecasted Estimates (Till 2035)
  • Table 15.8 Cancer Biologics Market in Europe: Distribution by Target Indication
  • Table 15.9 Cancer Biologics Market in Europe for Blood Cancer, Forecasted Estimates (Till 2035)
  • Table 15.10 Cancer Biologics Market in Europe for Lung Cancer, Forecasted Estimates (Till 2035)
  • Table 15.11 Cancer Biologics Market in Europe for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 15.12 Cancer Biologics Market in Europe for Breast Cancer, Forecasted Estimates (Till 2035)
  • Table 15.13 Cancer Biologics Market in Europe for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Table 15.14 Cancer Biologics Market in Europe for Skin Cancer, Forecasted Estimates (Till 2035)
  • Table 15.15 Cancer Biologics Market in Europe for Renal Cancer, Forecasted Estimates (Till 2035)
  • Table 15.16 Cancer Biologics Market in Europe for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Table 15.17 Cancer Biologics Market in Europe for Liver Cancer, Forecasted Estimates (Till 2035)
  • Table 15.18 Cancer Biologics Market in Europe for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Table 15.19 Cancer Biologics Market in Europe for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Table 15.20 Cancer Biologics Market in Europe for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Table 15.21 Cancer Biologics Market in Europe for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 15.22 Cancer Biologics Market in Europe for Brain Cancer, Forecasted Estimates (Till 2035)
  • Table 15.23 Cancer Biologics Market in Europe for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Table 16.1 Cancer Biologics Market in Asia-Pacific: Distribution by Type of Biologic
  • Table 16.2 Cancer Biologics Market in Asia-Pacific for Antibodies, Forecasted Estimates (Till 2035)
  • Table 16.3 Cancer Biologics Market in Asia-Pacific for Cell and Gene Therapies Forecasted Estimates (Till 2035)
  • Table 16.4 Cancer Biologics Market in Asia-Pacific for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Table 16.5 Cancer Biologics Market in Asia-Pacific for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Table 16.6 Cancer Biologics Market in Asia-Pacific for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Table 16.7 Cancer Biologics Market in Asia-Pacific for Peptides, Forecasted Estimates (Till 2035)
  • Table 16.8 Cancer Biologics Market in Asia-Pacific: Distribution by Target Indication
  • Table 16.9 Cancer Biologics Market in Asia-Pacific for Blood Cancer, Forecasted Estimates (Till 2035)
  • Table 16.10 Cancer Biologics Market in Asia-Pacific for Lung Cancer, Forecasted Estimates (Till 2035)
  • Table 16.11 Cancer Biologics Market in Asia-Pacific for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 16.12 Cancer Biologics Market in Asia-Pacific for Breast Cancer, Forecasted Estimates (Till 2035)
  • Table 16.13 Cancer Biologics Market in Asia-Pacific for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Table 16.14 Cancer Biologics Market in Asia-Pacific for Skin Cancer, Forecasted Estimates (Till 2035)
  • Table 16.15 Cancer Biologics Market in Asia-Pacific for Renal Cancer, Forecasted Estimates (Till 2035)
  • Table 16.16 Cancer Biologics Market in Asia-Pacific for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Table 16.17 Cancer Biologics Market in Asia-Pacific for Liver Cancer, Forecasted Estimates (Till 2035)
  • Table 16.18 Cancer Biologics Market in Asia-Pacific for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Table 16.19 Cancer Biologics Market in Asia-Pacific for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Table 16.20 Cancer Biologics Market in Asia-Pacific for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Table 16.21 Cancer Biologics Market in Asia-Pacific for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 16.22 Cancer Biologics Market in Asia-Pacific for Brain Cancer, Forecasted Estimates (Till 2035)
  • Table 16.23 Cancer Biologics Market in Asia-Pacific for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Table 17.1 Cancer Biologics Market in Rest of the World: Distribution by Type of Biologic
  • Table 17.2 Cancer Biologics Market in Rest of the World for Antibodies, Forecasted Estimates (Till 2035)
  • Table 17.3 Cancer Biologics Market in Rest of the World for Cell and Gene Therapies Forecasted Estimates (Till 2035)
  • Table 17.4 Cancer Biologics Market in Rest of the World for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Table 17.5 Cancer Biologics Market in Rest of the World for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Table 17.6 Cancer Biologics Market in Rest of the World for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Table 17.7 Cancer Biologics Market in Rest of the World for Peptides, Forecasted Estimates (Till 2035)
  • Table 17.8 Cancer Biologics Market in Rest of the World: Distribution by Target Indication
  • Table 17.9 Cancer Biologics Market in Rest of the World for Blood Cancer, Forecasted Estimates (Till 2035)
  • Table 17.10 Cancer Biologics Market in Rest of the World for Lung Cancer, Forecasted Estimates (Till 2035)
  • Table 17.11 Cancer Biologics Market in Rest of the World for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 17.12 Cancer Biologics Market in Rest of the World for Breast Cancer, Forecasted Estimates (Till 2035)
  • Table 17.13 Cancer Biologics Market in Rest of the World for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Table 17.14 Cancer Biologics Market in Rest of the World for Skin Cancer, Forecasted Estimates (Till 2035)
  • Table 17.15 Cancer Biologics Market in Rest of the World for Renal Cancer, Forecasted Estimates (Till 2035)
  • Table 17.16 Cancer Biologics Market in Rest of the World for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Table 17.17 Cancer Biologics Market in Rest of the World for Liver Cancer, Forecasted Estimates (Till 2035)
  • Table 17.18 Cancer Biologics Market in Rest of the World for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Table 17.19 Cancer Biologics Market in Rest of the World for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Table 17.20 Cancer Biologics Market in Rest of the World for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Table 17.21 Cancer Biologics Market in Rest of the World for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 17.22 Cancer Biologics Market in Rest of the World for Brain Cancer, Forecasted Estimates (Till 2035)
  • Table 17.23 Cancer Biologics Market in Rest of the World for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Table 19.1 Abbott: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.2 AbbVie: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.3 Amgen: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.4 AstraZeneca: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.5 BioNTech: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.6 Bristol Myers Squibb: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.7 Eli Lilly and Company: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.8 Gilead Sciences: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.9 GlaxoSmithKline: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.10 Johnson & Johnson: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.11 Merck: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.12 Novartis: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.13 Pfizer: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.14 Roche: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.15 Sanofi: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.16 Takeda Pharmaceuticals: Annual Revenues, Since FY 2021 (USD Billion)
  • Table 19.17 Cancer Biologics Market, Base Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Table 19.18 Cancer Biologics Market, Conservative Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Table 19.19 Cancer Biologics Market, Optimistic Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Table 19.20 Cancer Biologics Market for Antibodies, Forecasted Estimates (Till 2035)
  • Table 19.21 Cancer Biologics Market for Cell and Gene Therapies, Forecasted Estimates (Till 2035)
  • Table 19.22 Cancer Biologics Market for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Table 19.23 Cancer Biologics Market for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Table 19.24 Cancer Biologics Market for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Table 19.25 Cancer Biologics Market for Peptides, Forecasted Estimates (Till 2035)
  • Table 19.26 Cancer Biologics Market for Blood Cancer, Forecasted Estimates (Till 2035)
  • Table 19.27 Cancer Biologics Market for Lung Cancer, Forecasted Estimates (Till 2035)
  • Table 19.28 Cancer Biologics Market for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Table 19.29 Cancer Biologics Market for Breast Cancer, Forecasted Estimates (Till 2035)
  • Table 19.30 Cancer Biologics Market for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Table 19.31 Cancer Biologics Market for Skin Cancer, Forecasted Estimates (Till 2035)
  • Table 19.32 Cancer Biologics Market for Renal Cancer, Forecasted Estimates (Till 2035)
  • Table 19.33 Cancer Biologics Market for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Table 19.34 Cancer Biologics Market for Liver Cancer, Forecasted Estimates (Till 2035)
  • Table 19.35 Cancer Biologics Market for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Table 19.36 Cancer Biologics Market for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Table 19.37 Cancer Biologics Market for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Table 19.38 Cancer Biologics Market for Head and Neck Cancer, Forecasted Estimates (Till 2035)
  • Table 19.39 Cancer Biologics Market for Brain Cancer, Forecasted Estimates (Till 2035)
  • Table 19.40 Cancer Biologics Market for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Table 19.41 Cancer Biologics Market in North America, Forecasted Estimates (Till 2035)
  • Table 19.42 Cancer Biologics Market in the US, Forecasted Estimates (Till 2035)
  • Table 19.43 Cancer Biologics Market in Europe, Forecasted Estimates (Till 2035)
  • Table 19.44 Cancer Biologics Market in Germany, Forecasted Estimates (Till 2035)
  • Table 19.45 Cancer Biologics Market in France, Forecasted Estimates (Till 2035)
  • Table 19.46 Cancer Biologics Market in the UK, Forecasted Estimates (Till 2035)
  • Table 19.47 Cancer Biologics Market in Spain, Forecasted Estimates (Till 2035)
  • Table 19.48 Cancer Biologics Market in Rest of Europe, Forecasted Estimates (Till 2035)
  • Table 19.49 Cancer Biologics Market in Asia-Pacific, Forecasted Estimates (Till 2035)
  • Table 19.50 Cancer Biologics Market in India, Forecasted Estimates (Till 2035)
  • Table 19.51 Cancer Biologics Market in Japan, Forecasted Estimates (Till 2035)
  • Table 19.52 Cancer Biologics Market in South Korea, Forecasted Estimates (Till 2035)
  • Table 19.53 Cancer Biologics Market in China, Forecasted Estimates (Till 2035)
  • Table 19.54 Cancer Biologics Market in Rest of the World, Forecasted Estimates (Till 2035)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 3.3 Market Dynamics: Example List of Parameters
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 7.1 Abbott: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.2 AbbVie: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.3 Amgen: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.4 AstraZeneca: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.5 BioNTech: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.6 Bristol Myers Squibb: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.7 Eli Lilly and Company: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.8 Gilead Sciences: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.9 GlaxoSmithKline: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.10 Johnson & Johnson: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.11 Merck: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.12 Novartis: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.13 Pfizer: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.14 Roche: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.15 Sanofi: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 7.16 Takeda Pharmaceuticals: Annual Revenues, Since FY 2021 (USD Billion)
  • Figure 10.1 Cancer Biologics Market, Base Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 10.2 Cancer Biologics Market, Conservative Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 10.3 Cancer Biologics Market, Optimistic Scenario: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 11.1 Cancer Biologics Market for Antibodies, Forecasted Estimates (Till 2035)
  • Figure 11.2 Cancer Biologics Market for Cell and Gene Therapies, Forecasted Estimates (Till 2035)
  • Figure 11.3 Cancer Biologics Market for Oncolytic Viral Therapies, Forecasted Estimates (Till 2035)
  • Figure 11.4 Cancer Biologics Market for mRNA Therapies and Vaccines, Forecasted Estimates (Till 2035)
  • Figure 11.5 Cancer Biologics Market for Nucleotide-based Drugs, Forecasted Estimates (Till 2035)
  • Figure 11.6 Cancer Biologics Market for Peptides, Forecasted Estimates (Till 2035)
  • Figure 12.1 Cancer Biologics Market for Blood Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.2 Cancer Biologics Market for Lung Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.3 Cancer Biologics Market for Colorectal Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.4 Cancer Biologics Market for Breast Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.5 Cancer Biologics Market for Prostate Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.6 Cancer Biologics Market for Skin Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.7 Cancer Biologics Market for Renal Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.8 Cancer Biologics Market for Cervical and Gastric Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.9 Cancer Biologics Market for Liver Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.10 Cancer Biologics Market for Bladder Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.11 Cancer Biologics Market for Ovarian Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.12 Cancer Biologics Market for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.13 Cancer Biologics Market for Head and Neck Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.14 Cancer Biologics Market for Brain Cancer, Forecasted Estimates (Till 2035)
  • Figure 12.15 Cancer Biologics Market for Other Type of Cancer, Forecasted Estimates (Till 2035)
  • Figure 13.1 Cancer Biologics Market in North America, Forecasted Estimates (Till 2035)
  • Figure 13.2 Cancer Biologics Market in the US, Forecasted Estimates (Till 2035)
  • Figure 13.3 Cancer Biologics Market in Europe, Forecasted Estimates (Till 2035)
  • Figure 13.4 Cancer Biologics Market in Germany, Forecasted Estimates (Till 2035)
  • Figure 13.5 Cancer Biologics Market in France, Forecasted Estimates (Till 2035)
  • Figure 13.6 Cancer Biologics Market in the UK, Forecasted Estimates (Till 2035)
  • Figure 13.7 Cancer Biologics Market in Spain, Forecasted Estimates (Till 2035)
  • Figure 13.8 Cancer Biologics Market in Rest of Europe, Forecasted Estimates (Till 2035)
  • Figure 13.9 Cancer Biologics Market in Asia-Pacific, Forecasted Estimates (Till 2035)
  • Figure 13.10 Cancer Biologics Market in India, Forecasted Estimates (Till 2035)
  • Figure 13.11 Cancer Biologics Market in Japan, Forecasted Estimates (Till 2035)
  • Figure 13.12 Cancer Biologics Market in South Korea, Forecasted Estimates (Till 2035)
  • Figure 13.13 Cancer Biologics Market in China, Forecasted Estimates (Till 2035)
  • Figure 13.14 Cancer Biologics Market in Rest of the World, Forecasted Estimates (Till 2035)